Biopreservation Market Size, Share, Industry, Forecast and outlook (2024-2031)

Global Biopreservation Market is segmented By Biopreservation Media ( Freeze Media,  Hypothermic Storage, and Shipping Media), By Biopreservation Equipment (Freezers, Cryosystems, Thawing Equipment, Incubators, Centrifuges, Other Equipment), By Sample (Organs, Cells, Blood, Others), By End-User (Biobanks, Drug Discovery Industries, Hospitals, Others), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Size, Share, Outlook, and Opportunity Analysis, 2024-2031

Biopreservation Market Overview

[200 pages] Report on Global Biopreservation analyses the market size, shares, recent trends, competitive intelligence, and future market outlook. Demand from Drug Discovery Industries, Hospitals in North America is booming. Competitive rivalry intensifies with Biolife Solutions Inc, Merck KGaA, Biocision Llc and others operating in the market.

Biopreservation is the method by which the integrity and functionality of bodily products like DNA, stem cells, organs and tissues are conserved in unnatural conditions to prolong their viability.

Biopreservation Market Summary

For more insights Download Sample

Biopreservation Market Trends

The increasing investments and funding in research and development for regenerative therapies, the increasing prevalence of chronic diseases, and market strategies fuel the growth of the global biopreservation market during the forecast period.

Increasing investments and funding in regenerative therapies are boosting the global market growth during the forecast period.

The increasing investments and funding in regenerative therapies are boosting the global market growth during the forecast period. For instance, in April 2022, gene therapy secured $10.2 billion, cell-based companies secured $10.1 billion in funding, cell therapy followed with $2 billion, and tissue engineering biotech’s $341 million. Furthermore, according to Alliance for Regenerative Medicine, regenerative medicine and advanced therapy developers have raised $10.7B in financing in 2020, showing a 120% increase from the first half of 2019.

Moreover, market developments are accelerating the global biopreservation market growth during the forecast period. For instance, in April 2021, BioLife Solutions introduced a new high-capacity controlled freezer to cater to the cell and gene therapy market. Therefore, concerning the data mentioned, the increased funding in regenerative medicine is fueling the global biopreservation market growth.

The preservation issues and the high biopreservation cost will restrain the global biopreservation market growth.

However, the preservation issues and the high biopreservation cost will slow the growth of the global biopreservation market during the forecast period. For instance, a universal protocol does not apply to for biopreservation of all biologics even from the same category, such as the protocols developed for hematopoietic stem cells (HSCs) is not applicable to preserve mesenchymal stem cell (MSCs) and human embryonic stem cells (hESCs) since each cell type has its biology requires the preservation protocol to be based upon that. Furthermore, preserving biologics requires proper handling since a minute variation may damage the sample, which calls for proper training on handling. In addition, the initial collection and processing fees for stem cells cost from $1,200 for the only cord blood to $2,895 for cord blood, tissue and placenta stem cells. Thus, limiting the global biopreservation market growth during the forecast period.

COVID-19 Impact Analysis on Biopreservation Market

COVID- 19  pandemic has significantly impacted the global biopreservation market. COVID-19 made us face the fact that there is an increased need for novel treatment options for various kinds of diseases and make ourselves ready for any forthcoming situations like COVID-19, which has resulted in increased investment and funding in different research projects involving novel treatment approaches. For example, there are ongoing clinical trials on using Mesenchymal Stem Cells for add-on therapies in COVID-19 treatment, thus positively impacting the global biopreservation market growth.

Biopreservation Market Segmentation Analysis

Stem cells are expected to grow at the fastest CAGR during the forecast period (2022-2029)

Stem cells are predicted to dominate the global biopreservation market throughout the forecast period (2022-2029) owing to their benefits and the increasing research for their applications. Stem cells are unspecialized cells capable of transforming into characteristic cells such as blood, brain, muscle, bone, etc. Stem cells acquired from the umbilical cord are the youngest and have more significant potential than stem cells isolated from adults or other sources. They are used for treating over 80 life-threatening diseases, together with cancer, today. Approximately 500 clinical trials are currently active to treat conditions like Autism, Stroke, Diabetes, and Cerebral Palsy, therefore increasing the extent of future treatments. Stem cells isolated from umbilical cord blood have more potential to regenerate or repair damaged organs/tissues in regenerative medicine. Furthermore, the increasing number of research projects on stem cell applications for drug discovery, regenerative medicine, toxicology, cell therapy, and developmental biology ensure the dominance of stem cells over the global biopreservation market. Thus, from the data, the stem cell will grow at the fastest CAGR during the forecast period.

Global Biopreservation Market Geographical Share

The North American region holds the largest market share of the global biopreservation market

North America dominated the global biopreservation market and is estimated to dominate throughout the forecast period as the majority of the key market players, such as Biolife Solutions Inc., ThermoGenesis Holdings, Inc., Sigma-Aldrich Corporation, Thermo Fisher Scientific Inc., VWR Corporation, Biocision, Llc, Princeton Cryotech, Inc. and Custom Biogenic Systems Inc. holding a large share of the market through different market strategies such as product launches, collaborations, acquisitions and other are based in the United States. For instance, in October 2022, BioLife Solutions, Inc. partnered with CSafe, one of the largest active and passive temperature-controlled shipping solutions for pharmaceutical providers, to expand its supply chain solutions for the cell and gene therapy market. In January 2022, BioLife Solutions collaborated with Seattle Children's Therapeutics, a venture at Seattle Children's, bringing cutting-edge, curative technologies and therapies to defeat pediatric cancer and other diseases that impact children for improving the Manufacturing of viral vector and cell and gene therapy.

Furthermore, the increasing investment and funding in North America on regenerative medicines is contributing to the dominance of this region over the global biopreservation market. For example, the California Institute for Regenerative Medicine board has approved an additional investment of $80 million to expand its Alpha Clinic model dedicated to delivering stem cell and gene therapies to needy people. Thus, from the data mentioned, it is inferred that North America will dominate the global biopreservation market during the forecast period.

Biopreservation Market Companies and Competitive Landscape

The biopreservation market is competitive due to the involvement of key players in the research and development of new advanced products and the presence of local and global key players. Some key players are Biolife Solutions Inc., ThermoGenesis Holdings, Inc., Sigma-Aldrich Corporation, Thermo Fisher Scientific Inc., VWR Corporation, Merck KGaA, Eppendorf AG, Biocision, Llc, Princeton Cryotech, Inc. and Custom Biogenic Systems Inc. These key players hold the major share of the market through innovations, product launches, collaborations, acquisitions, and alliances. For instance, in May 2022, ThermoFisher partnered with LabShares to support the Greater Boston biotech ecosystem.

ThermoFisher Scientific

Overview:

ThermoFisher is a U.S.-based company founded in 1956. It is the world leader in serving science with annual revenue of approx. $40 billion has industry-leading brands such as Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon, and PPD.

Product Portfolio:

ThermoFisher Scientific has a vast product portfolio for biopreservation and has PSC Cryopreservation Kit: The kit contains xeno-free PSC Cryopreservation Medium and RevitaCell Supplement (100X) in combination. These reagents help minimize loss of cell viability, maximize post-thaw recovery, and minimize unwanted differentiation of pluripotent stem cells. This kit can also be used to cryopreserve and recover peripheral blood mononuclear cells (PBMCs) to improve post-thaw cell viability and recovery.

The global biopreservation market report would provide access to approximately 40+ market data tables, 45+ figures, and in the range of 200 (approximate) pages.